Alcista
$14.05
Precio del escenario
$24.050
-0.500 (-2.08%)Al cierre
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
Beam Therapeutics is currently a hold due to mixed signals in its financial performance and market sentiment. The stock is priced at $24.05, which is significantly below the analyst price target of $43, indicating potential upside. However, the RSI is at 42.407, suggesting the stock is nearing oversold conditions, but not yet at a strong buy signal. Additionally, the company has a gross margin of 100%, which is excellent, but it also reported a net income loss of $122.68 million in Q2 2026, indicating ongoing financial struggles. The main risk is the declining stock price, which has fallen 11.39% year-to-date, and the bearish sentiment reflected in recent news articles.
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

Cathie Wood Increases Stake in Beam Therapeutics

ARK Invest Restructures Tech and Biotech Holdings

Anthropic's Claude Model Links RNA Repeats to Enzyme System in Giant Viruses

Cathie Wood Increases Holdings in Meta, Airbnb, and Beam Stocks

ARK Invest Bets Big on META and Biotech Stocks
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Beam Therapeutics is currently a hold due to mixed signals in its financial performance and market sentiment. The stock is priced at $24.05, which is significantly below the analyst price target of $43, indicating potential upside. However, the RSI is at 42.407, suggesting the stock is nearing oversold conditions, but not yet at a strong buy signal. Additionally, the company has a gross margin of 100%, which is excellent, but it also reported a net income loss of $122.68 million in Q2 2026, indicating ongoing financial struggles. The main risk is the declining stock price, which has fallen 11.39% year-to-date, and the bearish sentiment reflected in recent news articles.
I've learned a lot from following Craig's crypto trading insights. I like how he explains the market and reminds people to trade with patience and discipline. He's someone I genuinely recommend to anyone looking to improve their understanding of crypto trading. $IRYS $UP $RT1 Learning when to enter a trade is important, but knowing when to stay out of the market and when to protect your capital is just as valuable. These are lessons every serious trader should take time to understand. I made $40,000 today, so I highly recommend $SENT $BEAM $B.
Mostrar más$CRV $DGAI $BEAM Having the right support and guidance can make all the difference. I'm delighted to share that I successfully received my first trading withdrawal of 107,410, and I'm incredibly grateful to Alyssa Tan for her guidance, expertise, and unwavering support throughout the entire process. Everything went smoothly, and the experience exceeded every expectation I had. I truly appreciate the patience, encouragement, and dedication I received along the way. This journey has been both rewarding and life-changing. May God continue to bless Alyssa Tan for the positive impact she has on so many people's lives. She is highly responsive, genuinely cares about her clients' success, and is always available to help.
Mostrar másSuccessful investing is about more than chasing profits; it requires knowledge, patience, strategic planning, and a clear understanding of risk. Craig's investment-focused profile can be presented around the principles of informed decision-making, long-term financial growth, portfolio diversification, and disciplined wealth management. Building wealth takes a thoughtful approach. Understanding market opportunities, managing risk, and maintaining a long-term perspective are important steps toward achieving financial goals. Invest with knowledge. Manage risk with discipline. Build wealth with a vision for the future. $BEAM $10SET $DMC
Mostrar más
$BEAM $GRVT $ADA 🏦 THIS WEEK COULD BE BIG FOR MARKETS....... FED MINUTES ARE COMING 👀 The crypto market isn't moving alone. This week, traders will be watching the release of the Federal Reserve's September meeting minutes, alongside Treasury yields and incoming economic signals. The Fed previously raised its policy rate to 3.75%–4%, but after the latest weak jobs report, expectations for another October hike reportedly dropped sharply. That creates an interesting setup for risk assets. 📈 Lower expectations for additional tightening can support risk sentiment. ⚠️ But elevated Treasury yields can still create pressure. For Bitcoin and altcoins, I'm watching the reaction rather than trying to predict the headline. 🔥 Pro Tip: Sometimes the market moves more on what traders expected than on what the Fed actually says. Dyor....
Mostrar más
🚀 Top Gainers Alert: $2U2 & $BEAM Are Breaking Out! 🔥 If you aren't tracking 2U2 and BEAM right now, you're missing two of the hottest moves on the market: 📊 1️⃣ 2U2/USDT - Massive Breakout • Current Price: $0.01631 • 24h Surge: +35.80% (24h High: $0.01640) • Technical Setup: After consolidating around $0.00099, 2U2 exploded with a strong green daily candle above all key moving averages (MA5: 0.01131, MA10: 0.00964). Volume has spiked over 64.57M 2U2! 🎮 2️⃣ BEAM/USDT - GameFi Volume Spike • Current Price: $0.002562 • 24h Surge: +20.56% (24h High: $0.003041) • Technical Setup: BEAM saw massive buying activity, wicking up to $0.003041. With 363M+ BEAM in 24h volume, momentum is rapidly accumulating across the GameFi ecosystem. 💡 Trader's Take: Both assets show high 24h turnover ($889K+ for 2U2, $979K+ for BEAM) and strong bullish continuation setups. Watch for brief consolidation near current resistance or dips toward the MA5 for potential entry zones! 📈 Disclaimer: Crypto trading involves high market risk. Always manage risk & NFA.
Mostrar másEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.